@article{IR,
      author = {Kumar, Pramod and Wallstrum, Alyssa and Reda, Moataz and  Wang, Ruijie and Ngamcherdtrakul, Worapol and Yantasee,  Wassana},
      url = {http://digitalcollections.ohsu.edu/record/43646},
      title = {Nanoparticles co-delivering doxorubicin & pd-l1  inhibitor to induce immunogenic cell death and enhance  anti-cancer immune response in lung cancer},
      publisher = {Oregon Health and Science University},
      abstract = {Non-small cell lung cancer (NSCLC) accounts for one in  five of all cancer deaths worldwide. Most patients are  diagnosed at advanced stages, resulting in a 5-year  survival rate of less than 20%. Recently, immune checkpoint  inhibitors (ICIs) for PD-L1 and PD-1 have received FDA  approval for the treatment of NSCLC. However, only a small  subset of patients (15-20%) respond to ICIs, and many of  these responders eventually relapse. Doxorubicin (DOX) is  an FDA-approved chemotherapeutic used in treating many  cancers, including lung cancer. However, it has  dose-dependent toxicity and patients develop resistance to  DOX over time.},
      number = {IR},
      doi = {https://doi.org/10.6083/bpxhc43646},
      recid = {43646},
      address = {2024},
}